The dominant tolerability signal in every trial of the class: incidence, timing relative to a dose step, duration, and the distinction between transient titration nausea and a persistent problem that warrants stopping.
Every summary I read says nausea is "the most common adverse event" and then quotes a single percentage, usually without saying which trial, which dose or which…
Eight weeks in on tirzepatide and I cannot work out which of two things is happening, and I think it matters. Version A: my appetite drive is genuinely reduced, food…
Fourteen weeks in, currently at the second-to-top dose, and I have been told repeatedly that the nausea settles. It has not settled. It has changed shape. Weeks 1-6…
I keep encountering the claim that GI side effects on GLP-1 agonists are driven by how fast you increase the dose rather than by the dose itself. It is repeated…
For reference: nausea · six · survodutide. Everything I have found on this is either a forum aside or a product page, neither of which I trust. I am comfortable with…
Conditions: nausea · retatrutide · TRIUMPH-3. The figures are clear enough; the question is what they mean and what they do not. I can supply the numbers if the…
Concretely: nausea · oral semaglutide. This is one of those things that everyone repeats and nobody derives. This matters practically, not just academically, because…
Numbers first: SURMOUNT-2 · nausea · 10 mg. I can parse the result. I am less sure what it licenses me to conclude. I have deliberately not looked at anyone else’s…
For reference: STEP 2 · nausea. I want to understand what this actually establishes, as opposed to what it is being used to imply. My concern is that I am being…
The particulars: PIONEER-1 · nausea · 14 mg. I have the document in front of me and I can read the numbers. What I cannot do is interpret them. I am reasonably…
For reference: nausea · ten · ecnoglutide. Everything I have found on this is either a forum aside or a product page, neither of which I trust. I am comfortable with…
I have three data points across nine months, which I hope is enough to see a trend. This is presented as though it settles something, and I am not convinced it does.…
The case in front of me: nausea · tirzepatide · SURMOUNT-1. The figures are clear enough; the question is what they mean and what they do not. I can supply the…
The case in front of me: nausea · tirzepatide · SURMOUNT-2. The figures are clear enough; the question is what they mean and what they do not. I can supply the…
The particulars: STEP 5 · nausea. I have the document in front of me and I can read the numbers. What I cannot do is interpret them. I am reasonably comfortable with…
What I have: SURMOUNT-1 · nausea. This is presented as though it settles something, and I am not convinced it does. I have two documents that appear to disagree,…
The case in front of me: nausea · oral semaglutide · PIONEER-1. I would like to know the limits of what can be inferred from this. What I am trying to avoid is…
The specifics, since they change the answer: SURMOUNT-OSA · nausea · 15 mg. I have the document in front of me and I can read the numbers. What I cannot do is…
Conditions: nausea · four · retatrutide. I have done this once and I suspect I got away with it rather than got it right. For context: I keep records of every batch,…
What I am working with: nausea · a GLP-1 receptor agonist. The empirical answer seems settled. The explanation does not. If the honest answer is that nobody knows, I…
What I have: STEP 2 · nausea · 1 mg. This is presented as though it settles something, and I am not convinced it does. I have two documents that appear to disagree,…
I have been logging for eleven weeks and I do not trust my own log. I thought I was averaging 110 g of protein. Then I weighed everything for four days out of…
I keep seeing two departures from the label ladder described. One is compression — two weeks per rung instead of four, halving the time to maintenance dose. The other…
For reference: TRIUMPH-3 · nausea · 8 mg. I have the document in front of me and I can read the numbers. What I cannot do is interpret them. I am reasonably…
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse results